Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016-2020): A Recapitulation of Chirality
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tamatam, Rekha | - |
dc.contributor.author | Shin, Dongyun | - |
dc.date.accessioned | 2023-05-16T00:44:04Z | - |
dc.date.available | 2023-05-16T00:44:04Z | - |
dc.date.created | 2023-05-15 | - |
dc.date.issued | 2023-03 | - |
dc.identifier.issn | 1424-8247 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87711 | - |
dc.description.abstract | Chirality is a major theme in the design, discovery, and development of new drugs. Historically, pharmaceuticals have been synthesized as racemic mixtures. However, the enantiomeric forms of drug molecules have distinct biological properties. One enantiomer may be responsible for the desired therapeutic effect (eutomer), whereas the other may be inactive, interfere with the therapeutic form, or exhibit toxicity (distomer). Classical chemical synthesis usually leads to a racemic mixture unless stereospecific synthesis is employed. To meet the requirements of single-enantiomeric drugs, asymmetric synthesis has evolved at the forefront of drug discovery. Asymmetric synthesis involves the conversion of an achiral starting material into a chiral product. This review emphasizes the methods used for synthesizing FDA-approved chiral drugs during 2016-2020, with a special focus on asymmetric synthesis by means of chiral induction, resolution, or chiral pool. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | PHARMACEUTICALS | - |
dc.title | Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016-2020): A Recapitulation of Chirality | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000956845300001 | - |
dc.identifier.doi | 10.3390/ph16030339 | - |
dc.identifier.bibliographicCitation | PHARMACEUTICALS, v.16, no.3 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85151680590 | - |
dc.citation.title | PHARMACEUTICALS | - |
dc.citation.volume | 16 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Tamatam, Rekha | - |
dc.contributor.affiliatedAuthor | Shin, Dongyun | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | FDA | - |
dc.subject.keywordAuthor | approve | - |
dc.subject.keywordAuthor | drug | - |
dc.subject.keywordAuthor | chiral | - |
dc.subject.keywordAuthor | asymmetric | - |
dc.subject.keywordAuthor | synthesis | - |
dc.subject.keywordPlus | RESEARCH-AND-DEVELOPMENT | - |
dc.subject.keywordPlus | ANTIVIRAL ACTIVITY | - |
dc.subject.keywordPlus | FINAL FORMS | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | DISCOVERY | - |
dc.subject.keywordPlus | POTENT | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.subject.keywordPlus | ACID | - |
dc.subject.keywordPlus | ROUTE | - |
dc.subject.keywordPlus | BRIVARACETAM | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.